Europe’s drug regulator on Wednesday discovered a doable link between AstraZeneca’s COVID-19 vaccine and uncommon blood clotting points in adults who had obtained the shot and stated it had considered all accessible proof.
“One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin,” the European Medicines Agency (EMA) stated.
The findings come as a significant hurdle within the world combat towards the pandemic and a shift within the stance of the regulator, which had final week backed the vaccine and stated there was no elevated danger of blood clots usually from the shot.
It can be a blow to AstraZeneca, which was a frontrunner within the race for making an efficient vaccine towards COVID-19 ever because it started working with the University of Oxford.
The EMA’s security committee, which was assessing the vaccine, has requested for extra research and modifications to the present ones to get extra data.